Highest-materiality recent filing
Revelation Biosciences reports Q4 and FY2025 results; cash $10.7M, net loss $8.9M
Cash and cash equivalents $10.7M as of Dec 31, 2025 vs $6.5M in 2024; net proceeds of $6.7M from warrant inducement in January 2026
Revelation Biosciences raises ~$7.3M via warrant exercise; issues new warrants
Two holders exercised 8,544,999 pre-split Class I warrants at $0.86/share, gross proceeds ~$7.3M.
Revelation Biosciences reaches FDA agreement on approval pathway for Gemini AKI treatment
FDA agreed single Phase 2/3 adaptive study (~300 patients) can support NDA for Gemini in AKI.
Revelation Biosciences reports positive Phase 1b Gemini results; plans Phase 2/3 AKI study in 2026
Phase 1b CKD study completed with positive results; Gemini rebalances inflammation at cellular level.
Revelation Biosciences Q3 net loss $1.9M, cash $12.7M; cash runway through Q3 2026
Net loss for Q3 2025 was $1.9M ($1.77 per share) vs $2.2M ($40.15) in Q3 2024.
Revelation Biosciences raises $9.6M via immediate exercise of existing warrants
$9.6M gross proceeds from exercise of 13,065,000 existing warrants at $2.20/share.
Gemini met primary safety endpoint; well-tolerated at target dose with only mild Grade I events.
Reverse stock split authorized at ratio 1:2 to 1:250, board to set exact ratio within one year.
Revelation Biosciences closes $4M public offering of common stock and warrants
Gross proceeds ~$4M from sale of 3,640,000 shares (or pre-funded warrants) plus warrants for up to 14,560,000 shares.
On May 23, 2025, George Tidmarsh, M.D., Ph.D., resigned from the Board of Directors of Revelation Biosciences, Inc. (the “Company”).
Max materiality 0.85 · Median 0.60 · Most common event other_material